These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

619 related items for PubMed ID: 19417028

  • 1. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S, Ennishi D, Asai H, Yokoyama M, Kojima K, Hatake K.
    Clin Cancer Res; 2009 May 15; 15(10):3624-32. PubMed ID: 19417028
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
    Saito B, Shiozawa E, Yamochi-Onizuka T, Adachi D, Nakamaki T, Tomoyasu S, Omine M, Mitsuya T, Takimoto M, Ota H.
    Pathol Int; 2004 Sep 15; 54(9):667-74. PubMed ID: 15363034
    [Abstract] [Full Text] [Related]

  • 3. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 15; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 4. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.
    Ann Hematol; 2003 Sep 15; 82(9):585-8. PubMed ID: 12898184
    [Abstract] [Full Text] [Related]

  • 5. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
    van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB.
    Clin Cancer Res; 2006 Jul 01; 12(13):4027-35. PubMed ID: 16818702
    [Abstract] [Full Text] [Related]

  • 6. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 7. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H, Yano T, Watanabe T, Uike N, Okamura S, Hanada S, Kawano F, Sunami K, Inoue N, Sawamura M, Nishiura T, Hotta T, Horibe K.
    Br J Haematol; 2008 Dec 24; 143(5):672-80. PubMed ID: 18950459
    [Abstract] [Full Text] [Related]

  • 8. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
    Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A.
    J Clin Oncol; 2008 Jul 01; 26(19):3166-75. PubMed ID: 18490650
    [Abstract] [Full Text] [Related]

  • 9. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B, Santos ES.
    Expert Rev Anticancer Ther; 2007 Mar 01; 7(3):257-73. PubMed ID: 17338647
    [Abstract] [Full Text] [Related]

  • 10. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
    Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
    Haematologica; 2008 Dec 01; 93(12):1829-36. PubMed ID: 18945747
    [Abstract] [Full Text] [Related]

  • 11. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X, Hu W, Qin X.
    Oncologist; 2008 Sep 01; 13(9):954-66. PubMed ID: 18779537
    [Abstract] [Full Text] [Related]

  • 12. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK, Levy R.
    J Clin Oncol; 2003 Nov 01; 21(21):3940-7. PubMed ID: 12975461
    [Abstract] [Full Text] [Related]

  • 13. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C.
    Clin Cancer Res; 2009 Jun 15; 15(12):4038-45. PubMed ID: 19509168
    [Abstract] [Full Text] [Related]

  • 14. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 15. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi JF, Patey M, Rousselet MC, Bene MC, Damotte D, Cornillet Lefebvre P, Martin A, Costes V, GOELAMS group.
    Hum Pathol; 2008 Feb 01; 39(2):194-200. PubMed ID: 17949786
    [Abstract] [Full Text] [Related]

  • 16. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H.
    Am J Surg Pathol; 2013 Apr 01; 37(4):563-70. PubMed ID: 23426122
    [Abstract] [Full Text] [Related]

  • 17. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
    Klepfish A, Gilles L, Ioannis K, Rachmilewitz EA, Schattner A.
    Ann N Y Acad Sci; 2009 Sep 01; 1173():865-73. PubMed ID: 19758239
    [Abstract] [Full Text] [Related]

  • 18. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, Milan S, Ferketich AK, Piro L, Leonard JP, Porcu P, Eisenbeis CF, Banks AL, Chen L, Byrd JC, Caligiuri MA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7046-53. PubMed ID: 17145827
    [Abstract] [Full Text] [Related]

  • 19. Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.
    Sacchi S, Pozzi S, Marcheselli L, Bari A, Luminari S, Angrilli F, Merli F, Vallisa D, Baldini L, Brugiatelli M, Italian Lymphoma Study Group.
    Cancer; 2007 May 15; 109(10):2077-82. PubMed ID: 17394190
    [Abstract] [Full Text] [Related]

  • 20. Responses to rituximab vary among follicular lymphoma B cells of different maturation stages.
    Mattila AM, Meri S.
    Scand J Immunol; 2008 Aug 15; 68(2):159-68. PubMed ID: 18702746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.